Research
Hormonal
Various treatment modalities, including GLP-1 agonists and dual GLP-1/GIP agonists, are reviewed for their effects on hepatic steatosis and fibrosis.
Practitioners should consider these treatment modalities for managing MASLD.
StrongSupportsmedium confidence
We look at the various conventional treatment modalities... as well as new treatment modalities like resmetirom, glucagon like peptide-1 (GLP-1) agonists, and dual GLP-1/GIP agonists for hepatic steatosis and fibrosis.
Why this rating
The claim is based on a review of existing literature.
Source
Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
V. Damle et al. · Journal of Diabetology · 2026
DOI 10.4103/jod.jod_85_25
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →